One hundred subjects suffering from a chronic progressive form of multiple sclerosis were randomly divided into two equal groups. Group 1 received Padma 28, two tablets three times a day, and group 2, the control, were treated only symptomatically. Treatment and observation lasted for 1 year. Examinations performed directly prior to the study and in the course of observation included: neurological state, visual and auditory evoked potentials, basic laboratory tests. A positive effect of Padma 28 was observed in 44% of patients with multiple sclerosis in the form of improvement of general condition, increase of muscle strength, decrease or disappearance of disorders affecting sphincters. In 41% of patients with initially an abnormal tracing of visual evoked potentials, an improvement or normalization was achieved. Of patients, who did not receive Padma 28 none felt better, moreover, 40% of them showed a deterioration. Tolerance of the drug was excellent.
"PADMA 28 has been registered in Switzerland since 1977 by Intercantonal Office for the Control of Medicines as a remedy to alleviate symptoms of claudication, impaired peripheral circulation, pain on walking, leg cramps, and paresthesia. A profitable influence of PADMA 28 was also observed in patients with atherosclerosis and in patients with multiple sclerosis  . In 1992, PADMA 28 was registered in Poland. "
[Show abstract][Hide abstract] ABSTRACT: PADMA 28 is a herbal multicompound remedy that originates from traditional Tibetan medicine and possesses anti-inflammatory, antioxidant, antimicrobial, angioprotecting, and wound healing properties. The aim of the present study was to evaluate the influence of this remedy on immunological angiogenesis and granulocytes metabolic activity in Balb/c mice. Mice were fed daily, for seven days, with 5.8 mg of PADMA (calculated from recommended human daily dose) or 0.085 mg (dose in the range of active doses of other herbal extracts studied by us previously). Results. Highly significant increase of newly formed blood vessels number in ex vivo cutaneous lymphocyte-induced angiogenesis test (LIA) after grafting of Balb/c splenocytes from both dosage groups to F1 hybrids (Balb/c × C3H); increase of blood lymphocytes and granulocytes number only in mice fed with lower dose of remedy; and significant suppression of metabolic activity (chemiluminescence test) of blood granulocytes in mice fed with higher dose of PADMA.
Conclusion. PADMA 28 behaves as a good stimulator of physiological angiogenesis, but for this purpose it should be used in substantially lower doses than recommended by producers for avoiding the deterioration of granulocyte function.
Mediators of Inflammation 06/2013; 2013:853475. DOI:10.1155/2013/853475 · 3.24 Impact Factor
"Padma 28 is a Tibetan herbal mixture consisting of 22 ingredients combined in a specific order. It has been reported to exert an immunomodulatory effect by affecting suppressor lymphocytes and may also induce the synthesis of interferon in humans.85 In a randomized controlled trial, treatment with Padma 28 appeared to be beneficial for patients with chronic progressive MS. "
[Show abstract][Hide abstract] ABSTRACT: Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system. Common manifestations include paresthesias, diplopia, loss of vision, numbness or weakness of the limbs, bowel or bladder dysfunction, spasticity, ataxia, fatigue, and mental changes. Four main patterns of MS are recognized: relapsing remitting, primary progressive, secondary progressive, and progressive relapsing. The cause of MS is unknown, although it appears to be an autoimmune disease. Much of what is known about MS has been learned from an animal model of the disease, experimental allergic encephalomyelitis.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.